Robbins LLP is Investigating Allegations that Merck & Co., Inc. (MRK) Misled Investors Regarding the Projected Revenue Outlook and Growth of Gardasil

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025. Merck is a global healthcare company.

The Allegations

According to the complaint, during the class period, defendants created the false impression that they possessed reliable information pertaining to Merck’s projected revenue outlook and anticipated growth of Gardasil while also minimizing risk from competition and drug approval developments, such as China’s approval to shift Gardasil to a 2-dose regimen. In truth, Merck’s optimistic reports of growth, claims of successful consumer activation and education in China, overall ability to drive demand, and efforts to downplay the impact of competition on Gardasil fell short of the reality.

The complaint alleges that on February 4, 2025, Merck announced it would no longer achieve the long-forecasted $11 billion in sales of Gardasil by 2030, as it would cease shipments of Gardasil to China “through at least midyear” to facilitate a “rapid reduction of inventory.”  On this news, Merck's stock price fell more than 9%, from $99.79 per share on February 3, 2025, to $90.74 per share on February 4, 2025.

What Now: You may be eligible to participate in the class action against Merck & Co., Inc. Shareholders who want to serve as lead plaintiff for the class must do so by April 14, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.  You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.